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CASE REPORT Open Access
Gain-of-function mutation in the voltage-
gated potassium channel gene KCNQ1 and
glucose-stimulated hypoinsulinemia - case
report
Jinyi Zhang1,2, Christian R. Juhl1, Louise Hylten-Cavallius1,2, Morten Salling-Olsen1,3, Allan Linneberg4,
Jens Juul Holst1,2, Torben Hansen2, Jørgen K. Kanters1* and Signe S. Torekov1,2*
Abstract
Background: The voltage-gated potassium channel Kv7.1 encoded by KCNQ1 is located in both cardiac myocytes
and insulin producing beta cells. Loss-of-function mutations in KCNQ1 causes long QT syndrome along with glucose-
stimulated hyperinsulinemia, increased C-peptide and postprandial hypoglycemia. The KCNE1 protein modulates Kv7.1
in cardiac myocytes, but is not expressed in beta cells. Gain-of-function mutations in KCNQ1 and KCNE1 shorten the
action potential duration in cardiac myocytes, but their effect on beta cells and insulin secretion is unknown.
Case presentation: Two patients with atrial fibrillation due to gain-of-function mutations in KCNQ1 (R670K) and KCNE1
(G60D) were BMI-, age-, and sex-matched to six control participants and underwent a 6-h oral glucose tolerance test
(OGTT). During the OGTT, the KCNQ1 gain-of-function mutation carrier had 86% lower C-peptide response after glucose
stimulation compared with matched control participants (iAUC360min = 34 pmol/l*min VS iAUC360min = 246 ± 71 pmol/
l*min). The KCNE1 gain-of-function mutation carrier had normal C-peptide levels.
Conclusions: This case story presents a patient with a gain-of-function mutation KCNQ1 R670K with low glucose-
stimulated C-peptide secretion, additionally suggesting involvement of the voltage-gated potassium channel KCNQ1 in
glucose-stimulated insulin regulation.
Keywords: Voltage-gated-potassium channels, Gain-of-function, Glucose metabolism
Background
Impaired function of the voltage-gated potassium channels
Kv7.1 (encoded by KCNQ1) and Kv11.1 (encoded by
KCNH2), caused by inheritable mutations or drugs leads to
long QT syndrome (LQTS) characterised by malignant
cardiac arrhythmias [1]. Moreover, inhibition of Kv7.1 and
Kv11.1 increases the glucose-stimulated insulin and C-
peptide secretion from the pancreatic beta cells and increases
glucagon-like peptide (GLP)-1 in mice [2, 3] and we have
previously shown that patients with LQT1 (due to loss of
function mutations in KCNQ1) and LQT2 (due to loss of
function mutations in KCNH2) have glucose-stimulated
hyperinsulinemia and postprandial hypoglycaemia [2, 4].
KCNQ1 is expressed in human beta cells [5] and blockage
of the channel increases glucose- stimulated insulin secre-
tion [3], and its overexpression impairs glucose-stimulated
insulin secretion [6]. KCNE1 encodes a human potassium
channel accessory (β) subunit, and modulates Kv7.1 in car-
diomyocytes, but does not seem to be expressed in beta
cells [7]. Gain-of-function mutations in either KCNQ1 or
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KCNE1 genes shorten the action potential duration and
effective refractory period in cardiomyocytes, increasing the
risk of atrial fibrillation (AF) [8, 9].
In this case study, we investigated glucose-stimulated
hormone secretion in two patients with AF due to con-
firmed gain-of-function mutations KCNQ1 R670K and
KCNE1 G60D, respectively. Expression in Xenopus laevis
oocytes of KCNQ1 R670K or Kv7.1 co-expressed with
KCNE1 G60D resulted in larger current amplitudes com-
pared with wildtype, confirming a gain-of-function pheno-
type [8, 9] of the mutations.
We hypothesized that patients with a KCNQ1 gain of
function mutation would have decreased glucose-induced
insulin and C-peptide secretion, whereas patients with
gain of function mutations in KCNE1 would be expected
to have normal insulin and C-peptide secretion upon
glucose stimulation.
Case presentation
We present two patients with AF who are confirmed het-
erozygous gain-of-function mutations carriers, recruited
from the outpatient clinic at Department of Cardiology,
Rigshospitalet, Denmark. One patient had persistent AF
and carried the KCNQ1 R670K mutation, while the other
patient had paroxysmal AF and carried the KCNE1 G60D
mutation. Neither patients had echocardiography abnor-
malities. For comparison with normal glucose metabolism
and ECG profiles, six control participants were BMI, age
and sex-matched with the AF patients recruited from the
Danish populations studies Inter99, Health 2006, Health
2010 and DanFund studies.
The methods used for the investigations and sample
analyzing were previously detalied described in [2]. Below
follows a condensed version. The patients and control par-
ticipants each underwent a 6-h oral glucose tolerance test
(OGGT) after overnight fasting. The patients did not take
medication the morning before the examination. In a rest-
ing state, baseline ECG and blood samples were taken 15,
10 and 0min before ingestion of a standard 75 g glucose
solution. During the following 6 h, ECG and blood
samples were taken every 15min for the first hour and
then every 30min for the remaining 5 h.
Height and weight were measured and BMI calculated
as height (m) / weight (kg)^2. Fat percentage was
measured using bioimpedance (Biodynamics BIA 310e,
Biodynamics, Seattle, WA).
Plasma glucose was measured using an automated
Vitros 5.1 FS/5600 analyzer (Ortho Clinical Diagnostics,
lower quantitation limit: 19.8 mg/Dl, intra- and interas-
say coefficients of variation: 0.025). Serum C-peptide
was measured using an automated Cobas e411 analyzer
(Roche) (analytic detection limit: 1.4–3 pmol/L, intra-
and interassay coefficients of variation < 0.04 and < 0.025
respectively. Plasma glucagon and GLP-1 were measured
using validated radioimmunoassays with a detection
limit < 1 pmol/L [10].
12-lead ECGs were recorded in a resting supine pos-
ition using a MAC1600 ECG machine (GE Healthcare,
Milwaukee, WI). Bazett’s formula (QTcB =QT/(RR)1/2)
and Fridericia’s formula (QTcF =QT/(RR)1/3) were used
to correct the QT interval by heart rate (RR).
For continuous glucose monitoring (CGM), the partici-
pants agreed to wear an iPro2 CGM (Medtronic, Watford,
U.K.) between 3 and 7 days. During this period each meal
was noted with time and meal composition.
HOMA-IR index was calculated as (fasting glucose
(mmol/l) x fasting insulin (μIU/ml))/22.5. HOMA-Beta
was calculated (20 x fasting insulin (μIU/ml))/(fasting
glucose (mmol/ml) - 3.5).
Findings: There were no differences in HbA1c, fasting
hemoglobin, fasting total cholesterol or fasting creatinine be-
tween the patients and the corresponding control partici-
pants. None of them had HbA1c levels ≥48mmol/mol
(Table 1).
At fasting state, the KCNQ1 R670K carrier presents with
slightly higher fasting insulin levels (but still within the
levels observed in the control participants (insulin 88 vs
range 14–137 pmol/L and C-peptide 774 vs 338–1226
Table 1 Subject characteristics of the KCNQ1 R670K carrier
(KCNQ1) and KCNE1 G60D carrier (KCNE1) and their BMI, sex and
age matched control participants. Subject characteristics and
fasting baseline of glucose and hormone levels of the mutation
carriers and their matched control participants (n = 6), and
baseline of ECG (n = 4), mean ± SD
KCNQ1 KCNE1 Control
Sex Male Male Male
Age 48 49 48 ± 1
BMI (kg/m2) 28.0 20.7 24.7 ± 4.3
Fat percentage 25.6 14.2 21.8 ± 5.8
HbA1c (mmol/mol) 31.0 34.0 34.0 ± 3.6
Hgb (mmol/l) 9.0 9.1 8.9 ± 0.8
Cholesterol (mmol/l) 4.0 5.9 4.7 ± 0.7
Creatinine (μmol/l) 62 71 77 ± 7
ECG characteristics in fasting state
QTcB (ms) 434.6 449.5 410.5 ± 26.8
QTcF (ms) 427.8 458.8 417.9 ± 17.2
Heart rate (beats/min.) 66.4 53.5 54.7 ± 10.7
Fasting glucose and hormone levels
Serum C-peptide (pmol/l) 774 403 576 ± 301
Serum Insulin (pmol/l) 88 21 42 ± 47
Plasma total GIP (pmol/l) 15 7 9 ± 2
Plasma total GLP-1 (pmol/l) 18 14 12 ± 2
Plasma Glucagon (pmol/l) 7 3 7 ± 4
Plasma Glucose (mmol/l) 5.6 5.2 5.1 ± 0.4
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pmol/L) and therefore increased HOMA-IR (3.1 vs 1.5 ±
1.2) and HOMA-Beta (123% vs 70 ± 55% compared to con-
trol participants). In contrast, during glucose stimulation
the KCNQ1 R670K carrier had a markedly blunted C-
peptide response and lower glucose levels compared to
control participants and the KCNE1 G60D carrier (Fig. 1
and S1). The glucose-stimulated GLP-1 response was also
blunted in the KCNQ1 GOF patient compared to control
participants, whereas glucagon response did not differ
among the examined participants (Fig. 1). During CGM for
3–7 days, the KCNQ1 mutation carrier had lower increase
in blood glucose levels within 1 h after carbohydrate rich
meals (mean increase of 0.8 ± 0.6mmol/l), compared to
both matched controls and the KCNE1 mutation carrier
(mean increase of 1.5 ± 0.4mmol/L and 1.7 ± 0.5mmol/L,
respectively) (Fig. S2).
The two patients had similar cardiac profiles as pre-
viously reported [8, 9] (Fig. 2).
Discussion and conclusions
We previously identified that patients with loss-of-function
mutations in KCNQ1 have increased glucose-stimulated C-
peptide and insulin secretion, but normal fasting levels [4].
Kv7.1 is expressed in human beta cells and participates in
depolarization-evoked insulin exocytosis [5]. In this case
study of a patient with gain of function mutation in
KCNQ1, we observed a lower glucose-stimulated C-peptide
and GLP-1 response compared to matched control partici-
pants. This may be due to shorter repolarization duration
in beta and L-cells cells, similar to what has been observed
for this variant with shortened action potential duration in
Xenopus laevis oocytes [8, 9]. Furthermore, this observation
is in agreement with studies of overexpression of KCNQ1
showing an increased glucose stimulated K+ current and
impaired and limited glucose stimulated insulin secretion
from beta-cells [6]. The KCNQ1 gain of function patient
had a low increase in glucose level after glucose ingestion
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Fig. 1 Plasma glucose and hormone responses to oral glucose tolerance test (OGTT). Six hour OGTT and results from Glucose (a), C-peptide (b),
Glucagon (c), and GLP-1 (d) of the KCNQ1 R670K carrier (KCNQ1) and KCNE1 G60D carrier (KCNE1) and their BMI, sex and age matched control
participants (n = 6), mean ± SEM
Zhang et al. BMC Endocrine Disorders           (2020) 20:38 Page 3 of 5
both during OGTT and during 7 days continuous glucose
monitoring, even though the C-peptide in response to glu-
cose stimulation were low. The patient reported that he bi-
cycled more than 20 km every weekday, which may explain
the high insulin sensitivity in the glucose-stimulated state
of the patient making him able to compensate for the low
C-peptide levels by increased glucose uptake in the mus-
cles. Intron variants in KCNQ1 associated with increased
risk of type 2 diabetes in genome wide association studies
seem to increase the function of KCNQ1, whereas siRNA
silencing decrease KCNQ1 function and increase exocytosis
of insulin [5].
Thus, with time and without exercise the KCNQ1 gain
of function patient may be in risk of type 2 diabetes.
We examined another AF patient with gain of function
mutation in KCNE1 that is not expressed in pancreas [7],
this patient had a similar C-peptide response compared to
the matched control participants. Hence KCNE1 does not
seem to function as a beta subunit of KCNQ1 in human
beta-cells.
Although limited by the very modest sample size, this
study provides additional suggestions of the involvement
of the voltage-gated potassium channel KCNQ1 in insulin
regulation.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12902-020-0513-x.
Additional file 1: Figure S1. Plasma glucose and C-peptide responses
to oral glucose ingestion in the KCNQ1 R670K carrier (KCNQ1) and KCNE1
G60D carrier (KCNE1) and their BMI, sex and age matched control partici-
pants. Control to KCNQ1 (R670K) (n = 2, men, BMI = 26.8 ± 0.7, age =
49.4 ± 2.3, fat% = 23.9 ± 3.5). Control to KCNE1 (G60D) (n = 2, men, BMI =
19.6 ± 1.3, age = 49.4 ± 0.6, fat% = 16.8 ± 6.6). Figure S2. Results from 3 to
7 day continuous glucose monitors (CGM). Increase of blood glucose
levels within 1 h after carbohydrate rich meals(a) and the mean glucose
levels for during the whole period(b) from the KCNQ1 (red) R670K carrier
(KCNQ1) and KCNE1 G60D carrier (KCNE1) (blue) and their matched con-
trol participants, means ± SEM.
Abbreviations
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